188 related articles for article (PubMed ID: 18086272)
1. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes.
Lynch HT; Silva E; Snyder C; Lynch JF
Breast J; 2008; 14(1):3-13. PubMed ID: 18086272
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
3. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
6. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.
Silva E; Gatalica Z; Snyder C; Vranic S; Lynch JF; Lynch HT
Breast J; 2008; 14(1):14-24. PubMed ID: 18086271
[TBL] [Abstract][Full Text] [Related]
7. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
[TBL] [Abstract][Full Text] [Related]
8. [Risk assessment for familial occurrence of breast cancer].
Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T
Zentralbl Gynakol; 1995; 117(8):423-34. PubMed ID: 7571905
[TBL] [Abstract][Full Text] [Related]
9. [Molecular genetics of hereditary breast carcinoma].
Hampl M; Chang-Claude J; Schwarz P; Saeger HD; Schackert HK
Zentralbl Chir; 1997; 122(2):67-73. PubMed ID: 9173760
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
11. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
12. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
13. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
14. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
16. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
17. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
18. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
[TBL] [Abstract][Full Text] [Related]
20. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
